Affimer

The Affimer protein scaffold – showing the two loops where random peptides can be inserted to create a protein binding surface

Affimer molecules[1] are small proteins that bind to target proteins with affinity in the nanomolar range.[2][3] These engineered non-antibody binding proteins are designed to mimic the molecular recognition characteristics of monoclonal antibodies in different applications.[2][4] These affinity reagents have been optimized to increase their stability,[5] make them tolerant to a range of temperatures and pH,[6] reduce their size, and to increase their expression in E.coli and mammalian cells.[2]

Development

Affimer proteins were developed initially at the MRC Cancer Cell Unit in Cambridge then across two laboratories at the University of Leeds.[7][8][9][10] Derived from the cysteine protease inhibitor family of cystatins, which function in nature as cysteine protease inhibitors,[11][12] these 12–14 kDa proteins share the common tertiary structure of an alpha-helix lying on top of an anti-parallel beta-sheet.[13]

Affimer proteins display two peptide loops that can all be randomized to bind to desired target proteins,[5] in a similar manner to monoclonal antibodies. Stabilization of the two peptides by the protein scaffold constrains the possible conformations that the peptides can take. This increases the binding affinity and specificity compared to libraries of free peptides, though can limit the target repertoire of Affimers.

Production

Phage display libraries of 109 randomized sequences[14] are used to screen for Affimer proteins that exhibit high-specificity binding to the target protein with binding affinities in the nM range.[5][15][16] The ability to direct in vitro screening techniques allows the identification of specific, high affinity Affimers. In vitro screening and development also mean that the target space for Affimers is not limited by the animal immune system. Affimers are generated using recombinant systems, so their generation is more rapid and reproducible compared to the production of polyclonal antibodies.[17]

Multimeric forms Affimers have been generated and shown to yield titres in the range of 200–400 mg/L under small-scale culture using bacterial host systems. Multimeric forms of Affimers with the same target specificity provide avidity effects in target binding.

Many different tags and fusion proteins, such as fluorophores, single-stranded DNA, His, and c-Myc tags can be conjugated to Affimers.[2][18][19][20][21][22] Specific cysteine residues can be introduced to the protein to allow thiol chemistry to uniformly orient Affimers on a solid support eg ELISA plates.[5][15][17][23][24] This flexible functionalisation of the Affimer molecule allows functionality across multiple applications and assay formats.

Properties

Affimers are recombinant proteins. As they are manufactured using recombinant bacterial production processes, the batch-to-batch consistency for Affimers is improved compared to polyclonal antibodies, overcoming some of the issues of reproducibility and security of supply.[2][3][17][25][26]

These synthetic antibodies were engineered to be stable, non-toxic, biologically neutral and contain no post-translational modifications or disulfide bridges.[7][8][10] Two separate loop sequences, incorporating a total of 12 to 36 amino acids, form the target interaction surface so interaction surfaces can range form 650–1000 Å. The large interaction surface results allows binding to target proteins.[5][7][10][15][17][18][27][28][29][30]

Applications

Affimer technology has been commercialised and developed by Avacta, which is developing these affinity reagents as tools for diagnostics and as biotherapeutics.

Reagents and Diagnostics

Affimer binders have been used across a number of platforms, including ELISA,[2][17][31] surface plasmon resonance,[32][31][33][34] affinity purification.[2][31][35][36] Affimers that inhibit protein-protein interactions can be produced with the potential to express these inhibitors in mammalian cells modify signalling pathways as cell therapies.[2][32][33][37][38]

Therapeutics

The small size and stability profile of Affimers combined with their human origin confer drug-like properties. This may represent advantages over antibodies in terms of tissue penetration, for example in solid tumours where Avacta are developing PD-L1 inhibitors as alternatives to Opdivo and Yervoy,[39] though requires half life modification to prevent rapid excretion through the kidney.

Affimers can be conjugated to form multimers for the design of therapeutics. Examples include the production of multi-specific Affimer molecules to albumin binders to increase their half-life in vivo and for use as the targeting moiety in chimeric receptors or modified to carry a toxin in Affimer-drug conjugates.[16][39][40]

Affimers as therapeutics are in discovery and preclinical development to tackle cancer, both via CAR-T cell therapy and as immune checkpoint inhibitors.[39][41][42][43] Early studies using ex vivo human samples showed low immunogenicity associated with the Affimer scaffold, at levels comparable to a marketed antibody therapeutic.[44] Furthermore, initial preclinical studies showed good efficacy and tolerability of the anti-PDL1 immuno-oncology Affimers in mice. It is anticipated that IND filing for the first Affimer therapeutic will occur in 2023.[16]

References

  1. ^ Proprietary name, owned by Avacta
  2. ^ a b c d e f g h Tiede C, Bedford R, Heseltine SJ, Smith G, Wijetunga I, Ross R, et al. (June 2017). "Affimer proteins are versatile and renewable affinity reagents". eLife. 6. doi:10.7554/elife.24903. PMC 5487212. PMID 28654419.
  3. ^ a b Klont F, Hadderingh M, Horvatovich P, Ten Hacken NH, Bischoff R (August 2018). "Affimers as an Alternative to Antibodies in an Affinity LC-MS Assay for Quantification of the Soluble Receptor of Advanced Glycation End-Products (sRAGE) in Human Serum". Journal of Proteome Research. 17 (8): 2892–2899. doi:10.1021/acs.jproteome.8b00414. PMC 6079930. PMID 30005571.
  4. ^ "Antibody Alternatives". The Scientist Magazine®. Retrieved 2018-10-18.
  5. ^ a b c d e Sharma R, Deacon SE, Nowak D, George SE, Szymonik MP, Tang AA, Tomlinson DC, Davies AG, McPherson MJ, Wälti C (June 2016). "Label-free electrochemical impedance biosensor to detect human interleukin-8 in serum with sub-pg/ml sensitivity". Biosensors & Bioelectronics. 80: 607–613. doi:10.1016/j.bios.2016.02.028. PMC 4785862. PMID 26897263.
  6. ^ Rawlings AE, Bramble JP, Tang AA, Somner LA, Monnington AE, Cooke DJ, McPherson MJ, Tomlinson DC, Staniland SS (October 2015). "Phage display selected magnetite interacting Adhirons for shape controlled nanoparticle synthesis". Chemical Science. 6 (10): 5586–5594. doi:10.1039/C5SC01472G. PMC 5949846. PMID 29861896.
  7. ^ a b c Woodman R, Yeh JT, Laurenson S, Ko Ferrigno P (October 2005). "Design and validation of a neutral protein scaffold for the presentation of peptide aptamers". Journal of Molecular Biology. 352 (5): 1118–33. doi:10.1016/j.jmb.2005.08.001. PMID 16139842.
  8. ^ a b Hoffmann T, Stadler LK, Busby M, Song Q, Buxton AT, Wagner SD, Davis JJ, Ko Ferrigno P (May 2010). "Structure-function studies of an engineered scaffold protein derived from stefin A. I: Development of the SQM variant". Protein Engineering, Design & Selection. 23 (5): 403–13. doi:10.1093/protein/gzq012. PMC 2851446. PMID 20179045.
  9. ^ Stadler LK, Hoffmann T, Tomlinson DC, Song Q, Lee T, Busby M, Nyathi Y, Gendra E, Tiede C, Flanagan K, Cockell SJ, Wipat A, Harwood C, Wagner SD, Knowles MA, Davis JJ, Keegan N, Ferrigno PK (September 2011). "Structure-function studies of an engineered scaffold protein derived from Stefin A. II: Development and applications of the SQT variant". Protein Engineering, Design & Selection. 24 (9): 751–63. doi:10.1093/protein/gzr019. PMID 21616931.
  10. ^ a b c Tiede C, Tang AA, Deacon SE, Mandal U, Nettleship JE, Owen RL, George SE, Harrison DJ, Owens RJ, Tomlinson DC, McPherson MJ (May 2014). "Adhiron: a stable and versatile peptide display scaffold for molecular recognition applications". Protein Engineering, Design & Selection. 27 (5): 145–55. doi:10.1093/protein/gzu007. PMC 4000234. PMID 24668773.
  11. ^ Turk V, Stoka V, Turk D (May 2008). "Cystatins: biochemical and structural properties, and medical relevance". Frontiers in Bioscience. 13 (13): 5406–20. doi:10.2741/3089. PMID 18508595.
  12. ^ Kondo H, Abe K, Emori Y, Arai S (January 1991). "Gene organization of oryzacystatin-II, a new cystatin superfamily member of plant origin, is closely related to that of oryzacystatin-I but different from those of animal cystatins". FEBS Letters. 278 (1): 87–90. doi:10.1016/0014-5793(91)80090-p. PMID 1993479. S2CID 40605067.
  13. ^ Turk V, Bode W (July 1991). "The cystatins: protein inhibitors of cysteine proteinases". FEBS Letters. 285 (2): 213–9. doi:10.1016/0014-5793(91)80804-C. PMID 1855589. S2CID 40444629.
  14. ^ Arrata I, Barnard A, Tomlinson DC, Wilson AJ (March 2017). "Interfacing native and non-native peptides: using Affimers to recognise α-helix mimicking foldamers" (PDF). Chemical Communications. 53 (19): 2834–2837. doi:10.1039/c6cc09395g. PMID 28217789.
  15. ^ a b c Zhurauski P, Arya SK, Jolly P, Tiede C, Tomlinson DC, Ko Ferrigno P, Estrela P (June 2018). "Sensitive and selective Affimer-functionalised interdigitated electrode-based capacitive biosensor for Her4 protein tumour biomarker detection" (PDF). Biosensors & Bioelectronics. 108: 1–8. doi:10.1016/j.bios.2018.02.041. PMID 29482002. S2CID 3549374.
  16. ^ a b c Basran A, Stanley E (2018-07-01). "Abstract 3776: Generation and formatting of an Affimer® biotherapeutic for the inhibition of the PD-L1/PD-1 pathway: Proof of concept in mouse". Cancer Research. 78 (13 Supplement): 3776. doi:10.1158/1538-7445.AM2018-3776. ISSN 0008-5472. S2CID 81376936.
  17. ^ a b c d e Xie C, Tiede C, Zhang X, Wang C, Li Z, Xu X, McPherson MJ, Tomlinson DC, Xu W (August 2017). "Development of an Affimer-antibody combined immunological diagnosis kit for glypican-3". Scientific Reports. 7 (1): 9608. Bibcode:2017NatSR...7.9608X. doi:10.1038/s41598-017-10083-w. PMC 5575301. PMID 28852111.
  18. ^ a b Schlichthaerle T, Eklund AS, Schueder F, Strauss MT, Tiede C, Curd A, Ries J, Peckham M, Tomlinson DC, Jungmann R (August 2018). "Site-Specific Labeling of Affimers for DNA-PAINT Microscopy" (PDF). Angewandte Chemie. 57 (34): 11060–11063. doi:10.1002/anie.201804020. PMID 29873161. S2CID 46950252.
  19. ^ Bedford R, Tiede C, Hughes R, Curd A, McPherson MJ, Peckham M, Tomlinson DC (August 2017). "Alternative reagents to antibodies in imaging applications". Biophysical Reviews. 9 (4): 299–308. doi:10.1007/s12551-017-0278-2. PMC 5578921. PMID 28752365.
  20. ^ Lopata A, Hughes R, Tiede C, Heissler SM, Sellers JR, Knight PJ, Tomlinson D, Peckham M (April 2018). "Affimer proteins for F-actin: novel affinity reagents that label F-actin in live and fixed cells". Scientific Reports. 8 (1): 6572. Bibcode:2018NatSR...8.6572L. doi:10.1038/s41598-018-24953-4. PMC 5920084. PMID 29700342.
  21. ^ Wang W, Guo Y, Tiede C, Chen S, Kopytynski M, Kong Y, Kulak A, Tomlinson D, Chen R, McPherson M, Zhou D (May 2017). "Ultraefficient Cap-Exchange Protocol To Compact Biofunctional Quantum Dots for Sensitive Ratiometric Biosensing and Cell Imaging". ACS Applied Materials & Interfaces. 9 (18): 15232–15244. doi:10.1021/acsami.6b13807. PMC 5432960. PMID 28421739.
  22. ^ Fisher MJ, Williamson DJ, Burslem GM, Plante JP, Manfield IW, Tiede C, Ault JR, Stockley PG, Plein S, Maqbool A, Tomlinson DC, Foster R, Warriner SL, Bon RS (December 2015). "Trivalent Gd-DOTA reagents for modification of proteins". RSC Advances. 5 (116): 96194–96200. Bibcode:2015RSCAd...596194F. doi:10.1039/c5ra20359g. PMC 4786947. PMID 27019702.
  23. ^ Weckman NE, McRae C, Ko Ferrigno P, Seshia AA (October 2016). "Comparison of the specificity and affinity of surface immobilised Affimer binders using the quartz crystal microbalance". The Analyst. 141 (22): 6278–6286. Bibcode:2016Ana...141.6278W. doi:10.1039/c6an01602b. PMID 27704086.
  24. ^ Koutsoumpeli E, Tiede C, Murray J, Tang A, Bon RS, Tomlinson DC, Johnson S (March 2017). "Antibody Mimetics for the Detection of Small Organic Compounds Using a Quartz Crystal Microbalance". Analytical Chemistry. 89 (5): 3051–3058. doi:10.1021/acs.analchem.6b04790. PMID 28192970.
  25. ^ "Anti-idiotypic binders for Trastuzumab validated in regulatory bioanalysis assay in collaboration with Covance". Avacta. Archived from the original on 2018-10-19. Retrieved 2018-10-19.
  26. ^ "Development and validation of anti-idiotypic Affmers to trastuzumab in a pharmacokinetic assay | Avacta". www.avacta.com. Archived from the original on 2018-10-19. Retrieved 2018-10-19.
  27. ^ Davis JJ, Tkac J, Laurenson S, Ko Ferrigno P (February 2007). "Peptide aptamers in label-free protein detection: 1. Characterization of the immobilized scaffold". Analytical Chemistry. 79 (3): 1089–96. doi:10.1021/ac061863z. PMID 17263340.
  28. ^ Davis JJ, Tkac J, Humphreys R, Buxton AT, Lee TA, Ko Ferrigno P (May 2009). "Peptide aptamers in label-free protein detection: 2. Chemical optimization and detection of distinct protein isoforms". Analytical Chemistry. 81 (9): 3314–20. doi:10.1021/ac802513n. PMID 19320493.
  29. ^ "Affimer binders improve diagnostic assay performance for C.difficile detection". Avacta. Archived from the original on 2018-10-19. Retrieved 2018-10-19.
  30. ^ "Development and characterisation of Affimer binders to 4 leading therapeutic antibodies | Avacta". www.avacta.com. Archived from the original on 2018-10-19. Retrieved 2018-10-19.
  31. ^ a b c "Avacta Scientist Dr Geoff Platt presents Affimer data in webinar | Avacta". www.avacta.com. Archived from the original on 2018-10-22. Retrieved 2018-10-22.
  32. ^ a b Robinson JI, Baxter EW, Owen RL, Thomsen M, Tomlinson DC, Waterhouse MP, Win SJ, Nettleship JE, Tiede C, Foster RJ, Owens RJ, Fishwick CW, Harris SA, Goldman A, McPherson MJ, Morgan AW (January 2018). "Affimer proteins inhibit immune complex binding to FcγRIIIa with high specificity through competitive and allosteric modes of action". Proceedings of the National Academy of Sciences of the United States of America. 115 (1): E72 – E81. doi:10.1073/pnas.1707856115. PMC 5776790. PMID 29247053.
  33. ^ a b Michel MA, Swatek KN, Hospenthal MK, Komander D (October 2017). "Ubiquitin Linkage-Specific Affimers Reveal Insights into K6-Linked Ubiquitin Signaling". Molecular Cell. 68 (1): 233–246.e5. doi:10.1016/j.molcel.2017.08.020. PMC 5640506. PMID 28943312.
  34. ^ Johnson A, Song Q, Ko Ferrigno P, Bueno PR, Davis JJ (August 2012). "Sensitive affimer and antibody based impedimetric label-free assays for C-reactive protein". Analytical Chemistry. 84 (15): 6553–60. doi:10.1021/ac300835b. PMID 22789061.
  35. ^ "Affimer® reagents facilitate affinity chromatography purification". www.drugtargetreview.com. Retrieved 2018-10-22.
  36. ^ Pechlivani, Nikoletta; Kearney, Katherine J.; Tiede, Christian; Cheah, Ramsah; Phoenix, Fladia; Ponnambalam, Sreenivasan; Ault, James R.; McPherson, Michael J.; Tomlinson, Darren C.; Ajjan, Ramzi A. (2022-05-01). "Affinity purification of fibrinogen using an Affimer column". Biochimica et Biophysica Acta (BBA) - General Subjects. 1866 (5): 130115. doi:10.1016/j.bbagen.2022.130115. ISSN 0304-4165. PMID 35240235. S2CID 247199635.
  37. ^ Kyle HF, Wickson KF, Stott J, Burslem GM, Breeze AL, Tiede C, Tomlinson DC, Warriner SL, Nelson A, Wilson AJ, Edwards TA (October 2015). "Exploration of the HIF-1α/p300 interface using peptide and Adhiron phage display technologies". Molecular BioSystems. 11 (10): 2738–49. doi:10.1039/c5mb00284b. PMID 26135796.
  38. ^ Heidelberger JB, Voigt A, Borisova ME, Petrosino G, Ruf S, Wagner SA, Beli P (April 2018). "Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function". EMBO Reports. 19 (4): e44754. doi:10.15252/embr.201744754. PMC 5891417. PMID 29467282.
  39. ^ a b c "Interview with Amrik Basran at Avacta Life Sciences". Drug Target Review.
  40. ^ "TMAC Affimer Drug Conjugates". Avacta. Archived from the original on 2018-10-22. Retrieved 2018-10-22.
  41. ^ Mulligan, Tom. "Avacta and Memorial Sloan Kettering Cancer Center in cell therapy research collaboration". Archived from the original on 2022-07-03. Retrieved 2018-10-22.
  42. ^ "Pipeline | Avacta". www.avacta.com. Retrieved 2018-10-22.
  43. ^ King R, Tiede C, Simmons K, Fishwick C, Tomlinson D, Ajjan R (February 2015). "Inhibition of complement C3 and fibrinogen interaction: a potential novel therapeutic target to reduce cardiovascular disease in diabetes". Lancet. 385 (Suppl 1): S57. doi:10.1016/s0140-6736(15)60372-5. PMID 26312879. S2CID 35622552.
  44. ^ "Affimer Technology: Results of PBMC Immunogenicity Testing". Avacta. Archived from the original on 2018-10-22. Retrieved 2018-10-22.

Read other articles:

Pusat Konvensi dan Hiburan Long Beach

Pusat Konvensi dan Hiburan Long BeachLong Beach Convention & Entertainment CenterLokasiLong Beach, California, Amerika SerikatKoordinat33°45′50″N 118°11′18″W / 33.76389°N 118.18833°W / 33.76389; -118.18833Koordinat: 33°45′50″N 118°11′18″W / 33.76389°N 118.18833°W / 33.76389; -118.18833OperatorASM GlobalDirenovasi1994, 2013Nama asliPusat Konvensi Long Beach (1978-90)Arena Umum Long BeachBanquet/ballroom9,700 (Top of th...

 

 

Parc national (France)

Pour les articles homonymes, voir Parc national et Parcs nationaux de France. Logotype de l'ancien établissement public national Parcs nationaux de France. En France, un parc national est une zone naturelle qui est classée du fait de sa richesse naturelle exceptionnelle. Il a la particularité d'être structuré en deux secteurs à la réglementation distincte : une zone de protection appelée « zone cœur » à la réglementation stricte de protection de la nature et une �...

 

 

Khanbaliq

Artikel ini tidak memiliki referensi atau sumber tepercaya sehingga isinya tidak bisa dipastikan. Tolong bantu perbaiki artikel ini dengan menambahkan referensi yang layak. Tulisan tanpa sumber dapat dipertanyakan dan dihapus sewaktu-waktu.Cari sumber: Khanbaliq – berita · surat kabar · buku · cendekiawan · JSTOR Artikel ini tidak memiliki kategori atau memiliki terlalu sedikit kategori. Bantulah dengan menambahi kategori yang sesuai. Lihat artikel yan...

X Koto Diatas, Solok

X Koto DiatasKecamatanBalerong Sari di Nagari Sulik Aia, X Koto DiatasNegara IndonesiaProvinsiSumatera BaratKabupatenSolokPemerintahan • Camat-Populasi • Total- jiwaKode Kemendagri13.02.12 Kode BPS1303120 Luas- km²Nagari/kelurahan-9 Nagari X Koto Diatas adalah sebuah Kecamatan di Kabupaten Solok, Sumatera Barat, Indonesia. Kecamatan ini berjarak sekitar 43 kilometer berkendara dari ibukota kabupaten Solok ke arah utara melalui Kota Solok. Pusat pemerintahannya be...

 

 

Bay Terrace, Staten Island

This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: Bay Terrace, Staten Island – news · newspapers · books · scholar · JSTOR (February 2013) (Learn how and when to remove this template message) Bay Terrace is the name of a neighborhood, centered around the street of the same name, on the East Shore of Staten Isl...

 

 

1995 World Championships in Athletics – Women's 1500 metres

Events at the1995 World ChampionshipsTrack events100 mmenwomen200 mmenwomen400 mmenwomen800 mmenwomen1500 mmenwomen5000 mmenwomen10,000 mmenwomen100 m hurdleswomen110 m hurdlesmen400 m hurdlesmenwomen3000 msteeplechasemen4 × 100 m relaymenwomen4 × 400 m relaymenwomenRoad eventsMarathonmenwomen10 km walkwomen20 km walkmen50 km walkmenField eventsHigh jumpmenwomenPole vaultmenLong jumpmenwomenTriple jumpmenwomenShot putmenwomenDiscus throwmenwomenHammer throwmenJavelin throwmenwomenCombined ...

Couche électronique

Pour un article plus général, voir Configuration électronique. Modèle de Bohr d'un atome à trois couches électroniques. En chimie et en physique atomique, une couche électronique d'un atome est l'ensemble des orbitales atomiques partageant un même nombre quantique principal n ; les orbitales partageant en plus un même nombre quantique azimutal ℓ forment une sous-couche électronique. Les termes couche et sous-couche sont hérités de la théorie des quanta du début du XXe...

 

 

Pierre Mignard

French painter (1612–1695) Pierre MignardPierre Mignard self-portraitBorn(1612-11-17)17 November 1612Troyes, FranceDied30 May 1695(1695-05-30) (aged 82)Paris, FranceDirector of the Académie de Peinture et de SculptureIn office1690–1695MonarchLouis XIV of FrancePreceded byCharles Le BrunSucceeded byNoël Coypel Pierre Mignard or Pierre Mignard I (17 November 1612 – 30 May 1695), called Mignard le Romain to distinguish him from his brother Nicolas Mignard, was a French painter known...

 

 

William Preston Lane Jr.

American politician (1892–1967) William LaneLane in 1950Chair of the National Governors AssociationIn officeJanuary 3, 1949 – June 19, 1949Preceded byLester C. HuntSucceeded byFrank Carlson52nd Governor of MarylandIn officeJanuary 3, 1947 – January 10, 1951Preceded byHerbert O'ConorSucceeded byTheodore McKeldinAttorney General of MarylandIn office1931–1935GovernorAlbert RitchiePreceded byThomas H. RobinsonSucceeded byHerbert O'Conor Personal detailsBornWilliam Presto...

Yale Repertory Theatre

Yale Repertory TheatreThe Yale Repertory Theatre, viewed from the Architecture Dept.AddressNew Haven, ConnecticutUnited States of AmericaOwnerYale UniversityTypeRegional theatreCapacity478Opened1966; 58 years ago (1966)Websitewww.yalerep.org BuildingGeneral informationArchitectural styleGothic revival architectureCompleted1846ClientThe Calvary Baptist ChurchTechnical detailsStructural systemBrick masonry Yale Repertory Theatre at Yale University in New Haven, Connecticut was...

 

 

俄亥俄州

  「俄亥俄」重定向至此。关于其他用法，请见「俄亥俄 (消歧义)」。 俄亥俄州 美國联邦州State of Ohio 州旗州徽綽號：七葉果之州地图中高亮部分为俄亥俄州坐标：38°27'N－41°58'N, 80°32'W－84°49'W国家 美國加入聯邦1803年3月1日，在1953年8月7日追溯頒定（第17个加入联邦）首府哥倫布（及最大城市）政府 • 州长（英语：List of Governors of {{{Name}}}]]） •&...

 

 

土库曼斯坦总统

土库曼斯坦总统土库曼斯坦国徽土库曼斯坦总统旗現任谢尔达尔·别尔德穆哈梅多夫自2022年3月19日官邸阿什哈巴德总统府（Oguzkhan Presidential Palace）機關所在地阿什哈巴德任命者直接选举任期7年，可连选连任首任萨帕尔穆拉特·尼亚佐夫设立1991年10月27日 土库曼斯坦土库曼斯坦政府与政治 国家政府 土库曼斯坦宪法 国旗 国徽 国歌 立法機關（英语：National Council of Turkmenistan） ...

Cathedral of Christ the Saviour

For other uses, see Cathedral of Christ the Saviour (disambiguation). Church of Christ the Saviour redirects here. For the church in Krym, see Church of Christ the Savior (Krym). Church in Moscow, RussiaCathedral of Christ the SaviourХрам Христа Спасителя Khram Khrista SpasitelyaThe new Cathedral of Christ the Saviour as viewed from the bridge over the Moscow RiverCathedral of Christ the Saviour55°44′40″N 37°36′20″E / 55.74444°N 37.60556°E...

 

 

Page County, Virginia

County in Virginia, United States County in VirginiaPage CountyCountyPage County Courthouse in February 2014 FlagSealLogoLocation within the U.S. state of VirginiaVirginia's location within the U.S.Coordinates: 38°37′N 78°29′W / 38.61°N 78.48°W / 38.61; -78.48Country United StatesState VirginiaFounded1831Named forJohn PageSeatLurayLargest townLurayArea • Total314 sq mi (810 km2) • Land311 sq mi (810...

 

 

David Dunbar Buick

Inventor and the founder of Buick Motor Company David Buick redirects here. For the New Zealand politician, see David Buick (politician). For the British financier, see David Buik. David Dunbar BuickBuick in 1891Born(1854-09-17)September 17, 1854Arbroath, Angus, ScotlandDiedMarch 5, 1929(1929-03-05) (aged 74)Detroit, Michigan, U.S.Burial placeWoodmere Cemetery, DetroitOccupation(s)Inventor, entrepreneurKnown forBuick Motor CompanySignature David Dunbar Buick (September 17, 1854 ...

Gannet

Genus of diving seabirds For other uses, see Gannet (disambiguation). GannetTemporal range: Early Miocene to recent 20–0 Ma PreꞒ Ꞓ O S D C P T J K Pg N Northern gannets (Morus bassanus) on Heligoland Northern gannet calls recorded on Grassholm Island, Wales Scientific classification Domain: Eukaryota Kingdom: Animalia Phylum: Chordata Class: Aves Order: Suliformes Family: Sulidae Genus: MorusVieillot, 1816 Type species Pelecanus bassanusLinnaeus, 1758 Species Morus bassanus Morus c...

 

 

Hujum

Upacara pembakaran kerudung di Andijan pada Hari Perempuan Internasional tahun 1927. Hujum (bahasa Rusia: Худжум; dari bahasa Turki, berarti ‘’penyerangan’’, bahasa Arab: هجوم) adalah serangkaian kebijakan yang diambil oleh Partai Komunis Uni Soviet atas ide Josef Stalin, yang bertujuan untuk menghapus semua bentuk ketidaksetaraan gender, terutama terkait penggunaan cadar dan praktik pengasingan perempuan yang banyak dilakukan di Asia Tengah.[1] Era tersebut ...

 

 

John Widegren

John Widegren John Widegren håller anförande vid Moderaternas partistämma, oktober 2021. Ledamot av Sveriges riksdag Mandatperiod2017 (ersättare)2018–2022 (ersättare)2022–2026 Valkrets Östergötlands län Född 4 februari 1980 (44 år)Röks församling, Östergötlands län Politiskt parti Moderaterna Yrke lantbrukare[1] John Erik Tommy Widegren, född 4 februari 1980 i Röks församling, Östergötlands län,[2] är en svensk politiker (moderat). Han är ordinarie riksda...

Vehículo eléctrico

Vehículo eléctrico Datos generalesPeríodo Años 1880-presenteConfiguraciónPropulsión EléctricaPlanta motrizMotor Eléctrico[editar datos en Wikidata] Un vehículo eléctrico es un vehículo propulsado por uno o más motores eléctricos.[1]​ Puede alimentarse a través de una fuente externa que suministre energía eléctrica,[2]​ o bien, pueden ser autónomos al tener instalados baterías,[3]​ paneles solares, o un generador eléctrico que transforme un combus...

 

 

كارلا وايت

هذه المقالة يتيمة إذ تصل إليها مقالات أخرى قليلة جدًا. فضلًا، ساعد بإضافة وصلة إليها في مقالات متعلقة بها. (أبريل 2019) كارلا وايت معلومات شخصية الميلاد 15 سبتمبر 1951   أوكلاند  الوفاة 9 مايو 2007 (55 سنة)   نيويورك  سبب الوفاة سرطان  مواطنة الولايات المتحدة  الحياة الع...